[Notice - March 19, 2026]

NOTICE OF SCHEDULED MAINTENANCE – ReBEC

Please be advised that the ReBEC system will undergo a scheduled maintenance outage, beginning at 6:00 p.m. on March 20, 2026 (Friday) and expected to end at 6:00 p.m. on March 22, 2026 (Sunday).

During this period, the system will be unavailable for access and for performing any operations. This measure is necessary to implement improvements and updates aimed at ensuring greater stability, security, and performance of the platform.

We recommend that users plan ahead to avoid any potential disruptions to their activities.

Thank you for your understanding.
ReBEC Coordination

PRIORITY SERVICES

The Brazilian Registry of Clinical Trials (ReBEC) presents the new fast tracks for clinical research and observational studies on INDIGENOUS PEOPLE AND TRADITIONAL COMMUNITIES and on NEGLECTED TROPICAL DISEASES (NTDs). Fast-track can reduce the normal approval period for clinical trials to less than 48 hours, if the documentation, information and any mandatory changes requested are provided by the registrant.

The already existing fast-tracks and the attendance to other studies will not be interrupted. Priority care is granted with a view to accelerating clinical research in epidemiological emergency situations and/or studies with the potential to reduce socioeconomic inequalities, keeping the perspective aligned with the forefront of ethics and transparency, diplomacy in health, scientific collaboration and diversity and specificities of recruitment and health care.

FAST-TRACKS IN OPERATION:

I - Indigenous Peoples, Traditional Communities, Human Migration and Refugee Movements – clinical research and observational studies dedicated to or preferably addressing traditional communities (quilombola, caiçara, faxinalense, among others), Indigenous peoples (within or outside legally demarcated territories), and refugee groups, taking into account the specificities established by regulation, on a case-by-case basis.

II - Neglected Tropical Diseases – Leprosy, Tuberculosis, Leishmaniasis, Schistosomiasis, Scabies, Chagas disease, Intestinal parasitoses, Viral hepatitis, Trachoma, Onchocerciasis, Human rabies transmitted by dogs.

III - National and International Public Health Emergencies – Mpox, Covid-19.

IV - Arboviruses – Zika, Dengue, Chikungunya, Malaria, Yellow fever.

V - WHO Prioritized Pathogens for Latin America – Studies dealing with World Health Organization prioritized pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Lassa fever, Cholera, Black Death (Plague), Bacillary dysentery or Shigellosis, Salmonella, Pneumonia, Urinary tract infection, MERS-CoV, SARS, Ebola virus (EVE), Marburg virus (MVE), Ebola virus (EVE) Sudan subtype, Hantavirus pulmonary syndrome (HPS), Hemorrhagic fever with renal syndrome (HFRS), Crimean-Congo hemorrhagic fever, Influenza A H1, Influenza A H2, Influenza A H3, Avian influenza (Influenza A H5N1), Avian influenza (Influenza A H6), Avian influenza H7 (Avian influenza H7), Avian influenza H10 or Avian influenza H10, Nipah disease, Viral hemorrhagic disease, Poliomyelitis, Hand-foot-and-mouth disease, Herpangina, Viral meningitis, Smallpox, Mpox, Human Immunodeficiency Virus (HIV), Venezuelan equine encephalitis (VEE).

VI - WHO Prioritized Prototype Pathogens for Latin America – Studies dealing with World Health Organization prioritized prototype pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Recombinant mastadenovirus, Mastadenovirus blackbeardi serotype 14, Mammarenavirus juninense, Mammarenavirus lujoense, Mamastrovirus virginiaense, Orthobornavirus bornaense, Orthoflavivirus encephalitidis, Orthoflavivirus nilense, Orthohepadnavirus hominoidae genotype C, Paslahepevirus balayani genotype 3, Protoparvovirus carnivoran, Orthobunyavirus oropoucheense, Phlebovirus riftense, Orthopicobirnavirus hominis, Enterovirus alphacoxsackie 71, Enterovirus deconjuncti 68, Metapneumovirus hominis, Orthopoxvirus vaccinia, Genus Vesiculovirus, Genus Rotavirus, Orthoreovirus mammalis.

VII - Studies on the impacts of climate change, the effects of scientific denialism, and health misinformation -The physical, mental, and social consequences of environmental and climate changes on human populations; The impact of extreme weather events and environmental degradation on infectious, chronic, or emerging diseases; The influence of denialist narratives and misinformation in Health on adherence to preventive measures, vaccination, treatments, and risk behaviors, as well as the physical and mental outcomes for human beings and populations.

INSTRUCTIONS:

We recommend reading the Registrant Handbook. Material available at LINK.

1. Register or log in and normally fill out the forms in Portuguese and English. For English, in case of difficulty, use the Google Translate tool (or another free translation tool).
2. Attach the mandatory ethics committee documentation and submit the form.
3. Register the service number on your Whatsapp. Send a message with your name and login. IT IS NOT NECESSARY NOR RECOMMENDED TO SEND YOUR PASSWORD.
4. A reviewer will respond to you. Choose the service modality: chat, audio recordings or voice call by appointment.
5. Your form will be proofread in both languages. Follow the remaining guidelines to finalize the approval.

CONTACTS:

Support is online, via chat, dedicated telephone line (see phone number below) and WhatsApp, from 9 am to 5 pm (Brasília time).

Administrative, priority and/or urgent matters outside office hours: plantao.rebec@gmail.com
Line 1: +55 21 97203-4750

ABOUT REBEC:

The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (OPAS) and the Oswaldo Cruz Foundation (FIOCRUZ). ReBEC's Executive Committee is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA).

04/22/2026  |   Carolyn Y. Johnson/Christopher Rowland  |  Washington Post

https://www.washingtonpost.com/health/2026/04/22/cancer-pancreatic-treatment-clinical-trial/ 

Pancreatic cancer has stymied treatment advances for decades. Data from new clinical trials shows promise.

Experimental therapies with radically different approaches are stirring a wave of optimism that survival rates could substantially improve for pancreatic cancer, one of the most stubbornly lethal forms of the disease.

Giving doctors and patients more options to standard chemotherapy would “increase shots on goal” and perhaps even make the dreaded diagnosis manageable over a number of years, according to experts.

The furthest along and generating the most excitement is a pill developed by Revolution Medicines, which inhibits a protein that signals cancer cells to multiply and drives tumor formation and growth. Phase 3 clinical trial results announced this month showed patients treated with the new drug, called daraxonrasib, had median survival of 13.2 months compared to 6.7 months for people receiving chemotherapy.

The Food and Drug Administration has put the drug on its speediest track for approval, meaning it could be approved this year. Ben Sasse, the former U.S. senator from Nebraska, is taking the drug to treat his pancreatic cancer and gave an interview to the New York Times about his experience, elevating public interest.

“We have moved from famine to feast in this disease,” said Shubham Pant, an oncologist who specializes in treating gastrointestinal cancers at the University of Texas MD Anderson Cancer Center. He spoke in San Diego on Tuesday at an American Association for Cancer Research conference session entitled, “Turning the tide in the fight against pancreatic…

04/23/2026  |  CHEO Research Institute

https://www.cheo.on.ca/en/news/cheo-research-institute-strengthens-pediatric-clinical-trials-in-canada.aspx 

The CHEO Research Institute has launched its new Clinical Trial Access Core and Clinical Investigation Unit (CIU) — a significant investment designed to expand pediatric clinical trial capacity in the region and strengthen Canada’s clinical trials ecosystem.

Located within the CHEO Research Institute, one of Canada’s top 40 research hospitals, the new Clinical Trial Access Core brings together the infrastructure, expertise and operational support needed to lead and host more pediatric clinical trials in the nation's capital.

Clinical trials are an essential part of pediatric care, particularly in rare and complex conditions where approved treatments may be limited or unavailable. By strengthening its ability to conduct high-quality pediatric trials, the CHEO Research Institute is enabling greater access to innovative, and potentially life-sustaining therapies closer to home.

“This investment strengthens Canada’s clinical trials infrastructure, supports government priorities to grow a competitive research ecosystem, and most importantly, ensures children and families have access to innovative care where, and when, they need it most,” said Dr. Jason Berman, CEO and Scientific Director of the CHEO Research Institute, and Vice-President of Research, CHEO.  

The launch of the Clinical Trial Access Core supports national efforts to strengthen Canada’s clinical trials capacity, enhance research competitiveness, and attract investment in life sciences and health innovation. By expanding pediatric trial infrastructure and operational readiness, the CHEO RI is helping Canada remain a destination for high-quality…

04/23/2026  |  Dan Schell  |  Clinical Leader

https://www.clinicalleader.com/doc/the-rise-and-stall-of-retail-pharmacy-clinical-trials-0001 

I’m warning you, what I’m about to say is a rumor.
You know, industry scuttlebutt.
Or as my daughter would say — the tea.

But I don’t think so.

See, more than one person (all of whom are smarter and more “connected” than me) has told me that Walgreens is getting out of the clinical trials game. Wait, I take that back, let me rephrase it … they are reassessing their commitment to pursuing their clinical trials strategy. I swear I’m not using AI for this stuff (maybe I should be!).

No matter how you phrase or spin it, I’m predicting something big is likely happening within the Walgreens Boots Alliance clinical trials business unit. Do I have proof? No. The company has not released any press release about this shift. When I did contact a representative from the company, they replied with the following:

“… please note that Walgreens/Sycamore will not be granting any formal interviews or furnish formal communications on the status of the business at this time.”

In case you don’t know, on August 28, 2025, Walgreens was acquired by Sycamore Partners, a mid-to-large private equity firm that took the retailer private. Fast forward nearly six months, and everything still seemed to be clicking with five Walgreens employees speaking in four different sessions at SCOPE about topics such patient engagement, RWE, and how retail pharmacies can improve access to clinical trials.

So, what changed since then?
I have no idea.

If I had to guess, considering a PE firm is now involved, I’d say it was a financial decision. But honestly, none of that matters,…

04/22/2026  |  Futura

https://www.futura-sciences.com/en/after-a-heart-attack-this-treatment-could-prevent-the-worst-and-researchers-are-optimistic_30717/ 

A treatment that targets the immune system could help prevent repeat heart attacks in people who have recently had one, according to results from an early-stage clinical trial in Cambridge. Two years after joining the study, none of the participants who received the treatment had suffered another heart attack.

The treatment, called aldesleukin, reduces inflammation in major blood vessels by boosting the activity of regulatory T cells, part of the immune system. Aldesleukin is already used at much higher doses to treat certain kidney cancers.

Regulatory T cells, a distinct type of white blood cell, play a crucial role in protecting the immune system, and their discovery was recently recognized with the 2025 Nobel Prize in Physiology or Medicine.

“We are delighted that our early-phase trial, which tested the very mechanism considered a game changer by the Nobel Prize committee, has shown encouraging results that we hope to answer conclusively in larger trials.”
Dr. Joseph Cheriyan
A consultant clinical pharmacologist at Cambridge University Hospitals NHS Foundation Trust who led the trials

In the United Kingdom, someone is admitted to the hospital every five minutes because of a heart attack. While seven out of ten people will survive a heart attack, many are left with damaged hearts, which can raise the risk of future attacks.

People who have had a heart attack often show high levels of inflammation in major blood vessels, and that is a strong sign they may be at risk of another one.

At present, there is no approved treatment that specifically targets…

04/22/2026 | César Ferro | Panorama Farmacêutico

https://panoramafarmaceutico.com.br/cristalia-promete-investir-o-que-for-necessario-na-polilaminina/ 

The laboratory has already allocated approximately R$ 150 million for the development of the molecule

Even after investing R$ 150 million in the development of polylaminin, Cristália continues to spare no effort in advancing the molecule through clinical trials. In an interview with Valor Econômico, the pharmaceutical company’s founder and chairman of the board, Ogari Pacheco, stated that the laboratory will contribute “whatever is necessary for the success of the innovation.”

The drug, which aims to regenerate spinal cord injuries, has sparked mixed reactions. On one hand, patients are seeking access to the experimental treatment through legal action. On the other, scientists outside the project are raising questions.

Led by scientist Tatiana Sampaio of the Federal University of Rio de Janeiro (UFRJ), the research has been supported by the company for eight years. The company’s funds financed the study and covered the cost of administering the drug to approximately 30 patients under compassionate use—when Anvisa authorizes its use in specific cases, even before formal approval.

Polylaminin patent is the first point of controversy
Cristália filed for a patent for the polylaminin manufacturing process at the national level in 2022. The following year, the application was also filed abroad, in markets such as the U.S., Europe, India, China, South Korea, and Latin America.

These applications are still under review, with no timeline for a decision. “Today, we are covered by this application, which provides us with protection both here and abroad,”…